Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients
复制标题
DOI：
10.1016/j.exphem.2015.08.004
复制
发表时间：
2015-12-01
影响因子：
2.6
通讯作者：
La Nasa, Giorgio
中科院分区：
文献类型：
--
作者：
Caocci, Giovanni;Martino, Bruno;La Nasa, Giorgio
有几个因素可以预测慢性髓性白血病（CML）的无治疗缓解（TFR），但关于自然杀伤细胞（NK）及其杀伤细胞免疫球蛋白样受体（KIRs）的作用的数据很少。研究了36例停止酪氨酸激酶抑制剂（TKI）治疗的CML患者的KIR和人类白细胞抗原（HLA）基因型，这些患者在达到深度分子反应（MR4.5）后停止治疗。KIR A单倍型纯合子患者的累积TFR显著更高（85.7% vs. 45.5%; p = 0.029）。年龄小、Bx单倍型、KIR3DS1/KIR3DL1存在/HLA-Bw4存在的组合与复发显著相关。KIR基因型可用于识别停止TKI治疗后可能维持MR4.5的患者。版权所有2015 ISEH -国际实验血液学学会Elsevier Inc.出版。
Several factors are predictive of treatment-free remission (TFR) in chronic myeloid leukemia (CML), but few data exist on the role of natural killer (NK) cells and their killer-cell immunoglobulin-like receptors (KIRs). KIR and human leukocyte antigen (HLA) genotypes were investigated in 36 CML patients who discontinued tyrosine kinase inhibitor (TKI) treatment after achieving deep molecular response (MR4.5). Cumulative TFR was significantly higher in patients homozygous for KIR A haplotype (85.7% vs. 45.5%; p = 0.029). Younger age, Bx haplotype, and the combination KIR3DS1/KIR3DL1 present/HLA-Bw4 present were significantly associated with relapse. KIR genotypes could prove useful in identifying patients that are likely to maintain MR4.5 after discontinuing TKI treatment. Copyright (C) 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.